- Nachrichtendetail
-
07.06.2024 17:40:09 - dpa-AFX: Geron Shares Rise After Rytelo Gets FDA Approval For Treatment Of Lower-risk MDS With TD Anemia
WASHINGTON (dpa-AFX) - Geron Corp. (GERN) shares surged by 17% on Friday
following the announcement of FDA approval for Rytelo (imetelstat) in treating
adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS),
with transfusion-dependent (TD) anemia.
GERN is trading on the Nasdaq at $4.55, up 17.09% or $0.66 per share. It has
traded between $1.64 and $5.15 in the past 52-week period.
The FDA's decision was based on the successful IMerge Phase 3 clinical trial,
which achieved its primary and secondary endpoints, showing that Rytelo led to
significantly higher rates of red blood cell transfusion independence compared
to the placebo.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
following the announcement of FDA approval for Rytelo (imetelstat) in treating
adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS),
with transfusion-dependent (TD) anemia.
GERN is trading on the Nasdaq at $4.55, up 17.09% or $0.66 per share. It has
traded between $1.64 and $5.15 in the past 52-week period.
The FDA's decision was based on the successful IMerge Phase 3 clinical trial,
which achieved its primary and secondary endpoints, showing that Rytelo led to
significantly higher rates of red blood cell transfusion independence compared
to the placebo.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
GERON CORP. (DEL.) DL-001 | 902213 | Frankfurt | 4,094 | 27.06.24 08:01:36 | -0,067 | -1,61% | 4,098 | 4,219 | 4,094 | 4,161 |
